XGN XGN
Company Profile ↓Company Overview
XGN (XGN) is a publicly traded company listed on with a market capitalization of $171.61M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 12.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $66.58M (+19.7% YoY); net profit $-19.95M.
- Trailing 12 Months Year-on-year growth — revenue +19.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.73% |
| 1 Year: | 19.65% |
Stock Price Performance
| 1 Year: | -23.57% |
| 6 Months: | +137.03% |
| 3 Months: | +63.89% |
| 1 Month: | +12.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 37.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 8.22M | 9.26M | 10.47M | 10.44M | 9.58M | 8.95M | 10.78M | 10.59M | 12.77M | 12.25M | 10.39M | 7.61M | 14.73M | 11.23M | 14.14M | 13.42M | 14.41M | 15.06M | 12.51M | 15.50M | 17.20M | 17.24M | 16.63M | 17.31M | 19.94M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.38M | 6.81M | 7.17M | 7.42M | 7.10M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.60M | 9.06M | 6.98M | 9.12M | 10.39M | 10.07M | 9.21M | 10.21M | 12.22M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.49M | 13.03M | 13.18M | 14.18M | 13.62M | - |
| Operating Income | - | - | -1.13M | -1.87M | -2.41M | -2.16M | -5.22M | -3.42M | -3.79M | -5.57M | -5.74M | -6.50M | -9.68M | -14.06M | -7.82M | -7.71M | -4.92M | -5.07M | -3.00M | -2.59M | -4.66M | -3.37M | -2.63M | -3.10M | -4.97M | -3.41M | -1.72M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.77M | -2.81M | -5.16M | -2.73M | -2.06M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 545.00K | 1.12M | 1.32M | 1.33M | 1.27M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.75M | -4.40M | -7.09M | -4.66M | -3.93M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 37.00K | 1.00K | 13.00K | 36.00K | - |
| Net Income | -2.79M | -2.15M | -1.76M | -2.70M | -2.79M | -3.14M | -5.56M | -3.36M | -4.31M | -6.21M | -6.41M | -7.18M | -10.27M | -14.66M | -8.10M | -7.69M | -5.01M | -5.42M | -3.36M | -2.97M | -5.03M | -3.75M | -4.44M | -7.09M | -4.67M | -3.97M | -3.20M |
| Diluted EPS | - | - | - | - | - | - | - | -0.27 | -0.34 | -0.48 | -0.38 | -0.42 | -0.60 | -0.86 | -0.47 | -0.44 | -0.28 | -0.31 | -0.19 | -0.16 | -0.28 | -0.20 | -0.21 | -0.31 | -0.20 | -0.17 | -0.13 |
| R&D Expense | - | - | 525.00K | 513.00K | 590.00K | 507.00K | 634.00K | 751.00K | 1.02M | 1.40M | 1.89M | 1.74M | 2.10M | 2.69M | 2.38M | 1.13M | 1.26M | 1.40M | 1.06M | 1.18M | 1.48M | 1.28M | 1.48M | 1.73M | - | 1.55M | 1.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.44M | 40.39M | 41.98M | - | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | - | - | - | - | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | - | - | - | - | 21.35M | 29.46M | 33.11M | 38.80M |
| Operating Expenses | - | - | - | - | 61.89M | 52.29M | 46.75M | 52.87M |
| Operating Income | -4.88M | -9.30M | -15.19M | - | -40.55M | -22.84M | -13.64M | -14.07M |
| EBITDA | - | - | - | - | -43.66M | -19.15M | -11.14M | -13.46M |
| Interest Expense | - | - | - | - | 2.45M | 2.33M | 2.23M | 4.32M |
| Pretax Income | - | - | - | - | -47.67M | -23.66M | -15.10M | -19.90M |
| Tax Provision | - | - | - | - | -282.00K | 33.00K | 12.00K | 51.00K |
| Net Income | -8.01M | -12.04M | -16.69M | - | -47.39M | -23.69M | -15.12M | -19.95M |
| Diluted EPS | - | - | -1.32 | - | -2.77 | -1.34 | -0.83 | -0.93 |
| R&D Expense | 2.12M | 2.18M | 3.57M | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 28.89M | 88.31M | 78.38M | - | 86.22M | 56.94M | 44.69M | 58.02M |
| Current Assets | - | - | - | - | - | 72.61M | 47.84M | 36.45M | 48.89M |
| Cash & Equivalents | - | 13.16M | 72.08M | 57.45M | - | 62.39M | 36.49M | 22.04M | 32.22M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 6.08M | 6.55M | 7.83M | 10.86M |
| Total Liabilities | - | 35.62M | 32.65M | 36.54M | - | 43.76M | 34.25M | 35.15M | 40.57M |
| Current Liabilities | - | 8.95M | 5.89M | 8.77M | - | 9.62M | 11.90M | 13.51M | 14.16M |
| Long Term Debt | - | 24.62M | 25.85M | 26.66M | - | 28.78M | 19.23M | 19.82M | 22.26M |
| Total Debt | - | - | - | - | - | 35.20M | 23.23M | 23.21M | 25.71M |
| Total Equity | -96.68M | -111.97M | 55.66M | 41.84M | - | 42.46M | 22.69M | 9.54M | 17.45M |
| Shares Outstanding | - | - | - | - | - | 16.55M | 17.05M | 17.64M | 22.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.30M | -9.71M | -14.08M | - | -32.14M | -14.46M | -13.28M | -13.62M |
| Investing Cash Flow | -199.00K | -103.00K | -455.00K | - | -4.32M | -804.00K | -515.00K | -626.00K |
| Financing Cash Flow | 11.42M | 68.73M | -97.00K | - | -489.00K | -10.63M | -663.00K | 24.43M |
| Capital Expenditure | -199.00K | -403.00K | -455.00K | - | -4.32M | -828.00K | -515.00K | -641.00K |
| Free Cash Flow | -9.50M | -10.11M | -14.54M | - | -36.46M | -15.29M | -13.79M | -14.27M |
| Net Change in Cash | - | - | - | - | -36.95M | -25.90M | -14.46M | 10.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 46.9% | 56.1% | 59.5% | 58.3% |
| Operating Margin % | -15.0% | -23.0% | -36.2% | - | -89.0% | -43.5% | -24.5% | -21.1% |
| Net Margin % | -24.7% | -29.8% | -39.8% | - | -104.0% | -45.1% | -27.2% | -30.0% |
| ROE % | 7.2% | -21.6% | -39.9% | - | -111.6% | -104.4% | -158.4% | -114.3% |
| ROCE % | -24.5% | -11.3% | -21.8% | - | -52.9% | -50.7% | -43.7% | -32.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Wexford Capital LP | 3.27% | 792.86K | $5.86M |
| 2 | Nano Cap New Millennium Growth Fund L P | 2.79% | 675.00K | $4.99M |
| 3 | Vanguard Capital Management LLC | 2.53% | 612.83K | $4.53M |
| 4 | FourWorld Capital Management, LLC | 2.46% | 596.53K | $4.41M |
| 5 | Silvercrest Asset Management Group, LLC | 2.12% | 514.76K | $3.80M |
| 6 | Kennedy Capital Management, LLC | 2.00% | 485.05K | $3.58M |
| 7 | Mink Brook Asset Management LLC | 1.96% | 475.94K | $3.52M |
| 8 | Jane Street Group, LLC | 1.33% | 322.50K | $2.38M |
| 9 | Acadian Asset Management. LLC | 1.28% | 310.08K | $2.29M |
| 10 | First Eagle Investment Management, LLC | 1.27% | 306.96K | $2.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XGN
Exagen (XGN) Q2 2026 Earnings Call Transcript
Record revenue and near break-even adjusted EBITDA signal progress toward profitability.
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution
Exagen now carries a modestly higher implied fair value, with the target shifting from about US$8.67 to roughly US$9.71 per share. Analysts link this change to a mix of optimism around the AVISE CTD autoimmune testing portfolio and caution …
Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance
Exagen (NASDAQ:XGN) delivered record quarterly revenue, narrowed losses, improved adjusted EBITDA, and increased its full-year revenue outlook as demand for its autoimmune testing portfolio continued to grow. Key Investor TakeawaysExagen (N…
Exagen Inc. Reports Second Quarter 2026 Financial Results
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2…
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, Augu…
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets
Exagen is back in focus as analysts refresh their price targets, with the latest models continuing to anchor around an unchanged US$8.67 fair value estimate. Recent Street commentary links these trimmed targets to updated assumptions about …
XGN — Frequently Asked Questions
What is the current share price of XGN?
As of 2026-09-16 18:39 PDT, XGN trades at $7.49 on NASDAQ/NYSE. Its 52-week range is $2.65 to $11.96.
What is the market capitalisation of XGN?
XGN has a market capitalisation of $171.61M on NASDAQ/NYSE.
What is the P/E ratio of XGN?
XGN trades at a trailing price-to-earnings (P/E) ratio of -8.05. Its price-to-book (P/B) ratio is 9.02.
What is the return on equity (ROE) of XGN?
XGN has a return on equity (ROE) of -114.34%. Its return on capital employed (ROCE) is -32.08%.
Is XGN a good stock to buy?
This page provides a data-driven analysis of XGN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.